ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells

Neoplasia

Volumn 11, Issue 2, 2009, Pages 157-166

  Clarhaut, Jonathan ^a   Gemmill, Robert M ^b   Potiron, Vincent A ^a,b   Ait Si Ali, Slimane ^c   Imbert, Jean ^d,e   Drabkin, Harry A ^b   Roche, Joëlle ^a,c  

^a UNIVERSITÉ DE POITIERS   (France)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c CNRS   (France)

^d INSERM   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; PROTEIN ZEB 1; REPRESSOR PROTEIN; SEMAPHORIN 3F; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; E BOX ELEMENT; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 61349127213     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81074     Document Type: Article

References (51)

1. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R, et al. (1996). Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12, 1289-1297.
2. Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI, and Minna JD (1996). Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci USA 93, 4120-4125.
3. Xiang RH, Hensel CH, Garcia DK, Carlson HC, Kok K, Daly MC, Kerbacher K, van den Berg A, Veldhuis P, Buys CH, et al. (1996). Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32, 39-48.
4. Semaphorin Nomenclature Committee (1999). Unified nomenclature for the semaphorins/collapsins. Cell 97, 551-552.
5. Luo Y, Raible D, and Raper JA (1993). Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75, 217-227.
6. Yazdani U and Terman JR (2006). The semaphorins. Genome Biol 7, 211.
7. Bielenberg DR and Klagsbrun M (2007). Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26, 421-431.
8. Neufeld G and Kessler O (2008). The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 8, 632-645.
9. Sun Q, Nawabi-Ghasimi F, and Basile JR (2008). Semaphorins in vascular development and head and neck squamous cell carcinoma-induced angiogenesis. Oral Oncol 44, 523-531.
10. PotironVA,Roche J, andDrabkinHA(2008). Semaphorins and their receptors in lung cancer. Cancer Lett; In press, online July 14, 2008. doi:10.1016/j.canlet.2008.05.032.
11. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, and Klagsbrun M (2004). Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114, 1260-1271.
12. Futamura M, Kamino H, Miyamoto Y, Kitamura N, Nakamura Y, Ohnishi S, Masuda Y, and Arakawa H (2007). Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression. Cancer Res 67, 1451-1460.
13. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, and Neufeld G (2004). Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64, 1008-1015.
14. Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, and Drabkin HA (2007). Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 67, 8708-8715.
15. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, and Naylor SL (2002). Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 62, 2637-2643.
16. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, and Klagsbrun M (1999). Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146, 233-242.
17. Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, and Roche J (2005). Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 7, 457-465.
18. Brambilla E, Constantin B, Drabkin H, and Roche J (2000). Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 156, 939-950.
19. Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, and Roche J (2005). Promoter characterization of semaphorin SEMA3F, a tumor suppressor gene. Biochim Biophys Acta 1730, 66-76.
20. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, et al. (2003). WNT7a induces E-Cadherin in lung cancer cells. Proc Natl Acad Sci USA 100, 10429-10434.
21. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, et al. (2006). Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66, 944-950.
22. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, DrabkinHA, and FranklinWA (2002).High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-Cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20, 2417-2428.
23. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, et al. (2007). The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26, 6979-6988.
24. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T, and Brabletz T (2006). A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131, 830-840.
25. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, et al. (2008). The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68, 537-544.
26. Peinado H, Olmeda D, and Cano A (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7, 415-428.
27. Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454.
28. Thiery JP and Sleeman JP (2006). Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142.
29. Turner J and Crossley M (1998). Cloning and characterization of mCtBP2, a co-repressor that associates with basic Kruppel-like factor and other mammalian transcriptional regulators. EMBO J 17, 5129-5140.
30. Furusawa T, Moribe H, Kondoh H, and Higashi Y (1999). Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor deltaEF1. Mol Cell Biol 19, 8581-8590.
31. Postigo AA and Dean DC (1999). ZEB represses transcription through interaction with the corepressor CtBP. Proc Natl Acad Sci USA 96, 6683-6688.
32. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y, and Shi Y (2003). Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422, 735-738.
33. Subramanian T and Chinnadurai G (2003). Association of class I histone deacetylases with transcriptional corepressor CtBP. FEBS Lett 540, 255-258.
34. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
35. Remacle JE, Kraft H, Lerchner W,Wuytens G, Collart C, Verschueren K, Smith JC, and Huylebroeck D (1999). New mode of DNA binding of multi-zinc finger transcription factors: deltaEF1 family members bind with two hands to two target sites. EMBO J 18, 5073-5084.
36. Dokmanovic M, Clarke C, and Marks PA (2007). Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5, 981-989.
37. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, Sancho E, Dedhar S, De Herreros AG, and Baulida J (2002). Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 277, 39209-39216.
38. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, et al. (2006). Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66, 46-51.
39. Wanami LS, Chen HY, Peiro S, Garcia de Herreros A, and Bachelder RE (2008). Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: Implications for tumor progression. Exp Cell Res 314, 2448-2453.
40. De Craene B, Gilbert B, Stove C, Bruyneel E, van Roy F, and Berx G (2005). The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res 65, 6237-6244.
41. Peinado H, Marin F, Cubillo E, Stark HJ, Fusenig N, Nieto MA, and Cano A (2004). Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci 117, 2827-2839.
42. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, et al. (2006). Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66, 9543-9556.
43. Andersen H, Mejlvang J, Mahmood S, Gromova I, Gromov P, Lukanidin E, Kriajevska M, Mellon JK, and Tulchinsky E (2005). Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells. Mol Cell Biol 25, 9138-9150.
44. Takeichi M (1993). Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5, 806-811.
45. AberleH, SchwartzH, and Kemler R (1996). Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 61, 514-523.
46. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, and Roche J (2005). Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7, 180-189.
47. Gui CY, Ngo L, Xu WS, Richon VM, and Marks PA (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101, 1241-1246.
48. Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, and Berger W (2004). SP-transcription factors are involved in basal MVP promoter activity and its stimulation by HDAC inhibitors. Biochem Biophys Res Commun 317, 235-243.
49. Wang J, Mahmud SA, Bitterman PB, Huo Y, and Slungaard A (2007). Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem 282, 28408-28418.
50. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, et al. (2005). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11, 77-84.
51. Ovcharenko I, Loots GG, Giardine BM, Hou M, Ma J, Hardison RC, Stubbs L, and MillerW(2005). Mulan: multiple-sequence local alignment and visualization for studying function and evolution. Genome Res 15, 184-194